- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00126334
Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot (CRIT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current standard of care for patients with heart attacks is to transfuse red blood cells when the hematocrit (red blood cell count) drops below 30 percent. However, there is little scientific basis for this current standard, and recent research has demonstrated that it is safe to allow the hematocrit (red blood cell count) to drop significantly lower in severely ill medical patients and in patients with heart disease undergoing major surgery. The investigators therefore propose this pilot trial to begin to determine whether or not it is safe to apply a more conservative blood transfusion strategy to patients with heart attacks.
In this study, patients who are within 72 hours of the onset of a heart attack and who are anemic (have a low red blood cell count) will be randomly assigned to one of two transfusion strategies while they are in the hospital: a liberal strategy of transfusing blood when the hematocrit falls below 30 percent (the current standard) or a conservative strategy of transfusing blood only when the hematocrit falls below 24 percent. It will then be determined which group fares better over the next 30 days.
The plan is to enroll 92 patients in this pilot trial in order to allow the researchers to plan for a much larger, definitive trial of this important question. It is anticipated that the conservative transfusion strategy will be similar to the standard (liberal) strategy in terms of patient outcomes.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
Washington, District of Columbia, United States, 20010
- Washington VA Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States
- Durham VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All of the following must be present:
- Acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB (CKMB) or troponin >upper limit of normal [ULN])
- Admission to CCU
- Hematocrit .30 or less
- Written, informed consent
Exclusion Criteria:
- Inability or unwillingness to receive red cell transfusions
- Active bleeding (overt blood loss accompanied by a decrease in hematocrit of at least 5% in the preceding 12 hours)
- Receipt of red cell transfusion within 7 days of randomization
- Prior severe transfusion reaction
- Pregnancy
- Imminent death
- Decision to provide limited care
- Age <21
- Participation in another clinical trial in which blood transfusion is a requirement or a component of a primary or secondary endpoint
- Previous participation in the CRIT Pilot
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
Liberal transfusion threshold
|
transfusion of 1 unit of PRBCs
|
|
Experimental: 2
Conservative transfusion threshold
|
transfusion of 1 unit of PRBCs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
In-hospital death
Time Frame: In-hospital
|
In-hospital
|
|
Recurrent myocardial infarction (MI)
Time Frame: In-hospital
|
In-hospital
|
|
New or worsening heart failure
Time Frame: In-hospital
|
In-hospital
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Death at 30 days
Time Frame: 30 days
|
30 days
|
|
Critical Care Unit (CCU) length of stay
Time Frame: In-hospital
|
In-hospital
|
|
Length of hospitalization
Time Frame: In-hospital
|
In-hospital
|
|
Death or recurrent MI at hospital discharge and 30 days
Time Frame: 30 days
|
30 days
|
|
Death or recurrent MI or new or worsening congestive heart failure (CHF) at 30 days
Time Frame: 30 days
|
30 days
|
|
In-hospital recurrent ischemia
Time Frame: In-hospital
|
In-hospital
|
|
In-hospital death or recurrent MI or new or worsening CHF or recurrent ischemia
Time Frame: In-hospital
|
In-hospital
|
|
Acute renal insufficiency (increase in serum creatinine of ≥ 0.5mg/dL)
Time Frame: In-hospitall
|
In-hospitall
|
|
Number of transfusions received per patient
Time Frame: In-hospital
|
In-hospital
|
|
Proportion of patients receiving at least one transfusion
Time Frame: In-hospital
|
In-hospital
|
|
Mean daily hematocrit
Time Frame: In-hospital
|
In-hospital
|
|
Transfusion-related reactions
Time Frame: In-hospital
|
In-hospital
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Howard A Cooper, M.D., Medstar Health Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2003-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.